Click here to see it on AdPharm

AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.

Her passion: Community service
Her power: Lantus 24-hour insulin

Ask your doctor about the easy-to-use Lantus SoloStar pen

Insulin glargine, marketed by Sanofi-Aventis under the name Lantus, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. Its advantage is that it has a duration of action of 24 hours, with a “less peaked” profile than NPH. Thus, it more closely resembles the basal insulin secretion of the normal pancreatic beta cells. In type 2 diabetes and in combination with a short acting sulfonylurea (drugs which stimulate the pancreas to make more insulin), it can offer moderate control of serum glucose levels. In the absence of endogenous insulin (Type 1 diabetes or depleted type 2), Lantus needs the support of a fast acting insulin taken with food to reduce the effect of prandially derived glucose. It is fasting glucose elevation which more significantly affects HbA1c and thus determines the progression of the long-term complications of diabetes mellitus.

More on Wikipedia

Brand name: Lantus
Generic name/category: Insulin glargine, Anti-diabetic drugs, Insulin therapies, Human proteins, Recombinant proteins, Peptide hormones
Company: Sanofi-Aventis
Country/Market: USA, North America
Indication(s)/use:
Target: Consumers (DTC)
Tagline: Tag
Medium: Print ad
Size/duration: One third of page plus one single-page
Publication/Aired: Diabetic Living – Fall 2009

To see all of this brand's ads on AdPharm, click here
1 views
Sep 07, 2009

Visit AdPharm.net for more pharmaceutical ads

Voici Abilify, indiqu?© dans le traitement de la schizophr?©nie.
Parce que les sympt??mes n?©gatifs font aussi partie de la route.

Une att?©nuation des sympt??mes positifs et n?©gatifs a ?©t?© d?©montr?©e avec Abilify.

Nouveau Abilify.

Here's Abilify, indicated for the treatment of schizophrenia.
Because negative symptoms are also part of the road.

New Abilify.

Aripiprazole (marketed as Abilify, Abilify Discmelt; also known as BMS 337039, OPC-14597, and APZ) was approved by the Food and Drug Administration (FDA) on November 15, 2002 for the treatment of schizophrenia, the sixth atypical antipsychotic medication of its kind. More recently, it received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder, and as an adjunct for the treatment of major depressive disorder. Aripiprazole was developed by Otsuka in Japan; in the U.S., Otsuka America markets the drug jointly with Bristol-Myers Squibb.

More on Wikipedia

Brand name: Abilify
Generic name/category: Aripiprazole, Atypical antipsychotics, Piperazines
Company: Bristol-Myers Squibb (BMS)
Country/Market: Canada, North America
Indication(s)/use: Schizophrenia
Target: Healthcare Professionals (HCP)
Medium: Print ad
Size/duration: double-page spread
Publication/Aired: Le M?©decin du Qu?©bec – September 2009

To see all of this brand's ads on AdPharm, click here
0 views
Sep 09, 2009

Visit AdPharm.net for more pharmaceutical ads

Agency: Euro RSCG Madrid

Brand name: Strepsils
Generic name/category: Throat Lozenges
Company: Reckitt Benckiser
Country/Market: Spain, Europe
Indication(s)/use: Sore throat
Target: Consumers (DTC)
Publication: 2009

To see all of this brand’s ads on AdPharm, click here